189 related articles for article (PubMed ID: 37878861)
1. Integrated Transcriptomic and Metabolomic Mapping Reveals the Mechanism of Action of Ceftazidime/Avibactam against Pan-Drug-Resistant
Hussein M; Allobawi R; Zhao J; Yu H; Neville SL; Wilksch J; Wong LJM; Baker M; McDevitt CA; Rao GG; Li J; Velkov T
ACS Infect Dis; 2023 Dec; 9(12):2409-2422. PubMed ID: 37878861
[TBL] [Abstract][Full Text] [Related]
2. Emergence of Ceftazidime-Avibactam Resistance Due to Plasmid-Borne
Shields RK; Chen L; Cheng S; Chavda KD; Press EG; Snyder A; Pandey R; Doi Y; Kreiswirth BN; Nguyen MH; Clancy CJ
Antimicrob Agents Chemother; 2017 Mar; 61(3):. PubMed ID: 28031201
[TBL] [Abstract][Full Text] [Related]
3. In vitro and in vivo bactericidal activity of ceftazidime-avibactam against Carbapenemase-producing
Zhang W; Guo Y; Li J; Zhang Y; Yang Y; Dong D; Zhu D; He P; Hu F
Antimicrob Resist Infect Control; 2018; 7():142. PubMed ID: 30479755
[TBL] [Abstract][Full Text] [Related]
4. Genomic characterization of a KPC-23-producing Klebsiella pneumoniae ST258 clinical isolate resistant to ceftazidime-avibactam.
Galani I; Antoniadou A; Karaiskos I; Kontopoulou K; Giamarellou H; Souli M
Clin Microbiol Infect; 2019 Jun; 25(6):763.e5-763.e8. PubMed ID: 30928562
[TBL] [Abstract][Full Text] [Related]
5. Emergence of ceftazidime/avibactam resistance in KPC-3-producing Klebsiella pneumoniae in vivo.
Göttig S; Frank D; Mungo E; Nolte A; Hogardt M; Besier S; Wichelhaus TA
J Antimicrob Chemother; 2019 Nov; 74(11):3211-3216. PubMed ID: 31365094
[TBL] [Abstract][Full Text] [Related]
6. Molecular analysis of clinical isolates of ceftazidime-avibactam-resistant Klebsiella pneumoniae.
Venditti C; Butera O; Meledandri M; Balice MP; Cocciolillo GC; Fontana C; D'Arezzo S; De Giuli C; Antonini M; Capone A; Messina F; Nisii C; Di Caro A
Clin Microbiol Infect; 2021 Jul; 27(7):1040.e1-1040.e6. PubMed ID: 33775814
[TBL] [Abstract][Full Text] [Related]
7. Synergistic effects of ceftazidime/avibactam combined with meropenem in a murine model of infection with KPC-producing Klebsiella pneumoniae.
Zheng M; Li FH; Liu J; Li WJ; Yin RX; Cai DT; Andrey DO; Zheng SL; Gales AC; Zhang WJ; Sun J; Liao XP; Yu Y
J Antimicrob Chemother; 2024 May; 79(5):1069-1080. PubMed ID: 38526879
[TBL] [Abstract][Full Text] [Related]
8. Ceftazidime-avibactam activity against a challenge set of carbapenem-resistant Enterobacterales: Ompk36 L3 alterations and β-lactamases with ceftazidime hydrolytic activity lead to elevated MIC values.
Castanheira M; Doyle TB; Hubler C; Sader HS; Mendes RE
Int J Antimicrob Agents; 2020 Jul; 56(1):106011. PubMed ID: 32417206
[TBL] [Abstract][Full Text] [Related]
9. A Ceftazidime-Avibactam-Resistant and Carbapenem-Susceptible Klebsiella pneumoniae Strain Harboring
Niu S; Chavda KD; Wei J; Zou C; Marshall SH; Dhawan P; Wang D; Bonomo RA; Kreiswirth BN; Chen L
mSphere; 2020 Aug; 5(4):. PubMed ID: 32848008
[TBL] [Abstract][Full Text] [Related]
10. Increased gene expression and copy number of mutated bla
Sun L; Li H; Wang Q; Liu Y; Cao B
BMC Microbiol; 2021 Aug; 21(1):230. PubMed ID: 34412588
[TBL] [Abstract][Full Text] [Related]
11. Activity of Ceftazidime-Avibactam Alone and in Combination with Ertapenem, Fosfomycin, and Tigecycline Against Carbapenemase-Producing
Ojdana D; Gutowska A; Sacha P; Majewski P; Wieczorek P; Tryniszewska E
Microb Drug Resist; 2019 Nov; 25(9):1357-1364. PubMed ID: 31295055
[TBL] [Abstract][Full Text] [Related]
12. Loss and gain of ceftazidime-avibactam susceptibility in a non-carbapenemase-producing K1-ST23 hypervirulent
Zhao J; Pu D; Li Z; Zhang Y; Liu X; Zhuo X; Lu B; Cao B
Virulence; 2024 Dec; 15(1):2348251. PubMed ID: 38697754
[TBL] [Abstract][Full Text] [Related]
13. Development of Resistance to Eravacycline by Klebsiella pneumoniae and Collateral Sensitivity-Guided Design of Combination Therapies.
Xu C; Wei X; Jin Y; Bai F; Cheng Z; Chen S; Pan X; Wu W
Microbiol Spectr; 2022 Oct; 10(5):e0139022. PubMed ID: 35972286
[TBL] [Abstract][Full Text] [Related]
14. Outbreak of Klebsiella pneumoniae ST11 Resistant To Ceftazidime-Avibactam Producing KPC-31 and the Novel Variant KPC-115 during COVID-19 Pandemic in Argentina.
Nicola F; Cejas D; González-Espinosa F; Relloso S; Herrera F; Bonvehí P; Smayevsky J; Figueroa-Espinosa R; Gutkind G; Radice M
Microbiol Spectr; 2022 Dec; 10(6):e0373322. PubMed ID: 36445147
[TBL] [Abstract][Full Text] [Related]
15. Activity of Ceftazidime-Avibactam Against Clinical Isolates of Klebsiella pneumoniae, Including KPC-Carrying Isolates, Endemic to New York City.
Manning N; Balabanian G; Rose M; Landman D; Quale J
Microb Drug Resist; 2018; 24(1):35-39. PubMed ID: 28590820
[TBL] [Abstract][Full Text] [Related]
16. Identification of KPC-112 from an ST15 Klebsiella pneumoniae Strain Conferring Resistance to Ceftazidime-Avibactam.
Shen S; Tang C; Ding L; Han R; Yin D; Yang W; Guo Y; Hu F
mSphere; 2022 Dec; 7(6):e0048722. PubMed ID: 36374086
[TBL] [Abstract][Full Text] [Related]
17. Isolation of a Ceftazidime-Avibactam-Resistant
Shen S; Shi Q; Han R; Guo Y; Yang Y; Wu S; Yin D; Hu F
Microbiol Spectr; 2022 Feb; 10(1):e0184021. PubMed ID: 35080422
[No Abstract] [Full Text] [Related]
18. Extensively Drug-Resistant Klebsiella pneumoniae Counteracts Fitness and Virulence Costs That Accompanied Ceftazidime-Avibactam Resistance Acquisition.
Eger E; Schwabe M; Schulig L; Hübner NO; Bohnert JA; Bornscheuer UT; Heiden SE; Müller JU; Adnan F; Becker K; Correa-Martinez CL; Guenther S; Idelevich EA; Baecker D; Schaufler K
Microbiol Spectr; 2022 Jun; 10(3):e0014822. PubMed ID: 35435751
[TBL] [Abstract][Full Text] [Related]
19. Effects of Klebsiella pneumoniae carbapenemase subtypes, extended-spectrum β-lactamases, and porin mutations on the in vitro activity of ceftazidime-avibactam against carbapenem-resistant K. pneumoniae.
Shields RK; Clancy CJ; Hao B; Chen L; Press EG; Iovine NM; Kreiswirth BN; Nguyen MH
Antimicrob Agents Chemother; 2015 Sep; 59(9):5793-7. PubMed ID: 26169413
[TBL] [Abstract][Full Text] [Related]
20. Ceftazidime/Avibactam Resistance in Carbapenemase-Producing Klebsiella pneumoniae.
Cui Q; Wang C; Wang Q; Qin J; Li M; Ding B; Shen Z
Emerg Infect Dis; 2023 Nov; 29(11):2398-2400. PubMed ID: 37877674
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
